M. Mondal

Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs

E. King, K. Okkenhaug, F. Ay, 2022, Nature.

Immunomodulatory effects of PI3Kδ inhibition in solid tumors – evaluation in a randomized phase II trial

E. King, R. Shaw, K. Okkenhaug, 2021 .

RNA-binding protein RBM3 intrinsically suppresses lung innate lymphoid cell activation and inflammation partially through CysLT1R

P. Vanderklish, G. Seumois, Sean J Lund, 2022, Nature Communications.

RNA-binding protein RBM3 negatively regulates innate lymphoid cells (ILCs) and lung inflammation

P. Vanderklish, G. Seumois, Sean J Lund, 2020, bioRxiv.

JAML immunotherapy targets recently activated tumor-infiltrating CD8+ T cells.

G. Thomas, P. Vijayanand, C. Ottensmeier, 2023, Cell reports.

Translational Modeling of Drug‐Induced Myelosuppression and Effect of Pretreatment Myelosuppression for AZD5153, a Selective BRD4 Inhibitor

E. Clark, TA Collins, M. Mondal, 2017, CPT: pharmacometrics & systems pharmacology.

DSETHVASAN: A NOVEL NANODRUG AGAINST SLEEPING SICKNESS

C. Ulrichs, R. Chandra, A. Goswami, 2011 .

Cytotoxic CD4+ tissue-resident memory T cells are associated with asthma severity.

G. Seumois, P. Vijayanand, C. Barber, 2023, Med.